Melanotan I

What is Melanotan I?

Melanotan I (afamelanotide, brand name Scenesse) is a synthetic 13-amino-acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It is approved in both the US and the EU for erythropoietic protoporphyria (EPP), a rare genetic condition that causes severe pain upon sun exposure, though the two regulators worded the claim differently: the FDA approved it in October 2019 to increase pain-free light exposure in adults with a history of EPP phototoxic reactions, while the EMA had approved it in December 2014 — under exceptional circumstances — for the prevention of phototoxicity. Unlike Melanotan II, afamelanotide is highly selective for the MC1R receptor, meaning it primarily stimulates skin pigmentation with minimal effects on sexual function, appetite, or cardiovascular parameters. It is administered as a subcutaneous implant by a healthcare provider every 60 days.

What Melanotan I Is Investigated For

Melanotan I (afamelanotide, brand name Scenesse) is one of the most clinically rigorous peptides on this site — approved in both the US and the EU for erythropoietic protoporphyria (EPP), a rare genetic condition where sun exposure causes severe pain. The two regulators granted different claims, and the difference is informative: the FDA approved it in October 2019 to increase pain-free light exposure, declining to grant the prevention-of-phototoxicity claim the EMA had granted in December 2014 under exceptional circumstances. The strongest evidence is the pair of Phase 3 RCTs reported together in NEJM, plus years of post-marketing observational data. Those two trials are usually quoted as one result, which they are not: in the US trial (94 patients, three implants) the median pain-free sun-exposure time over six months was 69.4 hours on afamelanotide versus 40.8 on placebo, while the European trial (74 patients, five implants) measured a different endpoint over nine months and found 6.0 hours versus 0.8. FDA's own analysis of the US trial, using a narrower 10am-to-6pm window, put the figures at 64.1 versus 40.5 hours. Real-world time-to-symptom-onset increased from ~12 minutes pre-treatment to ~120 minutes post-treatment. Investigational applications include vitiligo repigmentation combined with narrowband UVB phototherapy (JAMA Dermatology Phase 2), acute stroke neuroprotection (Phase 2a), and xeroderma pigmentosum — all genuinely early. The important clinical distinction is that Scenesse is distributed only through a restricted Clinuvel-certified EPP specialty network as a 60-day subcutaneous implant, not for cosmetic tanning; 'afamelanotide' or 'Melanotan I' sold online for tanning is research-chemical material outside the approved supply chain, and is pharmacologically and operationally distinct from Melanotan II despite the similar name.

History & Discovery

Afamelanotide — the molecule sold as Scenesse — traces back to the same University of Arizona melanocortin program in the 1980s and early 1990s that produced Melanotan II and, subsequently, bremelanotide. The Arizona group (Mac Hadley, Victor Hruby, and colleagues) was attempting to engineer alpha-MSH analogs that could induce skin pigmentation as a prospective non-UV photoprotection strategy. The lead linear analog — [Nle4, D-Phe7]-alpha-MSH, or NDP-alpha-MSH — substituted norleucine at position 4 for protease resistance and D-phenylalanine at position 7 for receptor affinity, producing a peptide approximately 100 to 1,000 times more potent than native alpha-MSH at melanocortin receptors with markedly extended duration of action. The Australian biotech Clinuvel Pharmaceuticals (originally Epitan) licensed the molecule in the early 2000s and pivoted from cosmetic-tanning ambitions to a rare-disease strategy: erythropoietic protoporphyria (EPP), a genetic ferrochelatase deficiency in which protoporphyrin IX accumulates in skin and produces severe, sometimes burn-like phototoxic pain on minimal light exposure. EPP patients live profoundly photo-restricted lives, and the unmet need was acute. Clinuvel developed a 16 mg biodegradable PLGA implant that delivers afamelanotide over approximately 60 days, inducing eumelanin synthesis as a UV-independent photoprotective barrier. Pivotal Phase 3 trials demonstrated significant reductions in phototoxic episodes and increases in pain-free sun exposure time. The European Medicines Agency approved Scenesse in 2014, the FDA in October 2019 — the first FDA approval of any therapy for EPP. Long-term observational cohorts now extend safety and effectiveness data beyond eight years of continuous use. Clinuvel has continued to investigate broader dermatologic applications (vitiligo, xeroderma pigmentosum) and acute-stroke neuroprotection, though those remain investigational. By 2026 the monopoly was ending, on two fronts at once. Disc Medicine's bitopertin, a glycine transporter GlyT1 inhibitor taken orally, attacks EPP upstream by reducing protoporphyrin IX production rather than shielding skin from it. Ross and colleagues reported the open-label BEACON study in 26 adults and adolescents (Clin Exp Dermatol May 2026, PMID 41527357), Yeung and colleagues reported the placebo-controlled AURORA trial in 75 patients with PPIX reductions of 29.6% at 20 mg and 49.8% at 60 mg (J Am Acad Dermatol April 2026, PMID 41390126), and the pivotal Phase 3 APOLLO trial in 183 patients completed on 8 September 2026 with an expanded-access programme now open. The more direct competitive threat is dersimelagon (MT-7117), Mitsubishi Tanabe's oral MC1R agonist — the same receptor target as afamelanotide, delivered as a daily tablet rather than a bimonthly implant placed by a certified clinician — which has completed two Phase 3 trials of 184 and 165 patients with a 286-patient extension still running. Neither is FDA-approved, so Scenesse remains the only approved US option; but the 2026 review by Barman-Aksoezen and colleagues (Expert Opin Pharmacother March 2026, PMID 41885813) frames the pressure precisely, noting that afamelanotide does not address the underlying disease mechanism and is approved only in adults, leaving children and adolescents without an option. Mechanistic and real-world work on afamelanotide itself also continued. Griffin and colleagues characterized its acute effects on UVR erythemal and melanogenic responses in nine healthy volunteers (Photochem Photobiol Sci September 2026, PMID 42678656) — an exploratory study, and one whose authors hold a research collaboration with Clinuvel rather than being independent of the sponsor. An Australian multi-site study (Br J Dermatol May 2026, PMID 41902471) documented persistent diagnostic-delay and access issues that shape which EPP patients ever reach a specialty Scenesse-treating centre, and a porphyria-landscape review (Am J Clin Dermatol July 2026, PMID 42213346) sets out the clinical spectrum in which Scenesse now sits.

How It Works

Melanotan I mimics the body's natural tanning hormone (alpha-MSH) but is much more potent and longer-lasting. It activates the MC1R receptor on melanocytes, stimulating them to produce eumelanin — the dark, protective pigment that shields DNA from UV damage. Unlike Melanotan II, it is highly selective for this one receptor, so it primarily affects pigmentation without significant effects on sexual function or appetite.

Afamelanotide ([Nle4, D-Phe7]-alpha-MSH) is a selective MC1R agonist. MC1R activation on epidermal melanocytes triggers the cAMP-PKA signaling cascade, leading to CREB phosphorylation and upregulation of MITF (microphthalmia-associated transcription factor). MITF drives transcription of tyrosinase, TRP-1, and TRP-2 — the key melanogenic enzymes — resulting in increased eumelanin synthesis. Beyond melanogenesis, MC1R signaling enhances nucleotide excision repair (NER) of UV-induced DNA photoproducts, including cyclobutane pyrimidine dimers. Studies show a 50% decrease in epidermal sunburn cells and significant reduction in thymine dimer formation. MC1R activation also modulates antioxidant pathways and inflammatory responses. In EPP, afamelanotide induces protective eumelanin independently of UV stimulation, reducing sensitivity to protoporphyrin IX-mediated phototoxicity.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Melanotan I:

• 01Long-term melanoma and skin-cancer signal — over a decade of post-marketing surveillance has not identified a clear melanoma signal in EPP cohorts, but the pharmacological activation of MC1R on melanocytes warrants continued long-term monitoring, particularly as treatment durations now extend beyond a decade in some patients.
• 02Pediatric EPP use — labeled indication is for adults; pediatric EPP patients have substantial unmet need but trial data and approval in younger populations are limited.
• 03Vitiligo efficacy beyond proof-of-concept — the Phase 2 combination trial with narrowband UVB showed promise but Phase 3 data and approval in vitiligo are not established.
• 04Acute stroke neuroprotection — Phase 2a proof-of-concept work has been published, but adequately powered efficacy trials in acute ischemic stroke are pending.
• 05Xeroderma pigmentosum and other UV-vulnerable genetic conditions — mechanistic rationale for benefit is strong (MC1R activation enhances nucleotide excision repair) but clinical-trial data is preliminary.
• 06Optimal dosing intervals across latitudes and individual phenotypes — the 60-day cadence is a population average, and individualized dosing based on symptom burden and protoporphyrin levels has not been formally optimized, and no trial has tested whether dosing cadence should track latitude, phototype or erythrocyte protoporphyrin IX concentration rather than the calendar.
• 07Head-to-head comparison with emerging EPP therapies — and there are now two credible ones. Bitopertin, an oral glycine-transporter (GlyT1) inhibitor from Disc Medicine, reduces protoporphyrin IX production upstream rather than shielding skin downstream; its placebo-controlled Phase 2 (AURORA, PMID 41390126) cut PPIX by up to 49.8% and its Phase 3 (APOLLO, 183 patients) completed in September 2026. Dersimelagon (MT-7117, Mitsubishi Tanabe) is the more direct threat, because it is an oral MC1R agonist hitting the same receptor as afamelanotide without an implant, and it has completed two Phase 3 trials. No head-to-head trial against afamelanotide exists for either, and whether the approaches are complementary, competitive, or best in different patient subsets is unaddressed.
• 08Pediatric and adolescent EPP — the label is adults-only, and both oral challengers have enrolled adolescents. A 2026 review (PMID 41885813) makes the point bluntly: afamelanotide does not address the underlying disease mechanism and is approved only in adults, leaving children and adolescents without an approved option.

Forms & Administration

Afamelanotide is available as Scenesse, a 16mg biodegradable subcutaneous implant (poly(DL-lactide-co-glycolide) matrix). It is administered by a healthcare professional into the subcutaneous tissue above the anterior supra-iliac crest every 60 days, typically before and during periods of increased sun exposure. It is only available through a restricted distribution program for the approved EPP indication.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Scenesse is FDA-approved only for adults with erythropoietic protoporphyria. Off-label use for cosmetic tanning, vitiligo, or other indications is not supported by the approved product distribution or by adequate safety/efficacy data outside EPP. Compounded or research-chemical 'afamelanotide' is not equivalent to the approved implant.

Timeline of Effects

Common Questions

Who Melanotan I Is NOT For

Drug & Supplement Interactions

Documented clinical drug interactions for afamelanotide are minimal — peptide proteolytic clearance does not engage classical CYP-mediated metabolism. Theoretical and clinically observed considerations cluster around overlapping pigmentary or melanocyte-active therapies. Concomitant use of psoralen-UVA (PUVA), narrowband UVB phototherapy, or other phototherapy modalities can be combined with afamelanotide in research settings (the published vitiligo combination trials used afamelanotide plus narrowband UVB), but additive effects on pigmentation should be anticipated and managed clinically. Patients on hydroxychloroquine or other agents associated with pigmentary changes should be aware of additive cosmetic effects. Afamelanotide does not interact in clinically significant ways with the medications EPP patients commonly take for porphyrin management or hepatic support. As with any chronic specialty therapy, patients should disclose all prescription, OTC, and supplement use to their prescriber. There is no documented interaction with sunscreens — use of topical photoprotection alongside afamelanotide is encouraged rather than discouraged.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions